IBM & Boehringer Ingelheim | Advancing Therapeutic Antibody Research
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading